Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.56 |
| ▸ | REN | P00797 | 2/20 | 0.53 |
| ▸ | NMBR | P28336 | 3/20 | 0.52 |
| ▸ | ECE1 | P42892 | 5/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.50 |
| ▸ | IL1RN | P18510 | 1/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18854326 | 0.98 | GHSR (0.56) | GHSRRENNMBRECE1MMP2 | |
| SCHEMBL18854271 | 0.94 | GHSR (0.56) | GHSRRENNMBRECE1ERAP2 | |
| SCHEMBL18862442 | 0.94 | GHSR (0.56) | GHSRRENNMBRECE1ERAP2 | |
| SCHEMBL18862334 | 0.90 | GHSR (0.57) | GHSRRENNMBRECE1ERAP2 | |
| SCHEMBL18854267 | 0.88 | GHSR (0.55) | GHSRRENNMBRERAP2IL1RN | |
| SCHEMBL18857368 | 0.88 | GHSR (0.66) | GHSRERAP2 | |
| SCHEMBL18854323 | 0.88 | GHSR (0.59) | GHSRREN | |
| SCHEMBL29426361 | 0.83 | GHSR (0.60) | GHSRERAP2 | |
| SCHEMBL18854269 | 0.83 | GHSR (0.60) | GHSRREN | |
| SCHEMBL18854331 | 0.83 | GHSR (0.56) | GHSRREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20170137801-A1 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-18 | — | — | US | disclosed |
| US-20170137801-A1 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | ASGR1, LDLR, HAVCR2 | GHSR 1190/4885REN 2795/4885NMBR 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.